NASDAQ:LUCD - US54948X1090 - Common Stock
The current stock price of LUCD is 1.38 USD. In the past month the price increased by 39.41%. In the past year, price increased by 71.45%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.1 | 231.15B | ||
ISRG | INTUITIVE SURGICAL INC | 56.46 | 162.94B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.91 | 158.98B | ||
SYK | STRYKER CORP | 30.69 | 150.76B | ||
MDT | MEDTRONIC PLC | 16.79 | 119.10B | ||
BDX | BECTON DICKINSON AND CO | 13.4 | 54.82B | ||
IDXX | IDEXX LABORATORIES INC | 53.33 | 51.24B | ||
EW | EDWARDS LIFESCIENCES CORP | 31.5 | 47.53B | ||
RMD | RESMED INC | 28.67 | 40.09B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.91 | 33.84B | ||
DXCM | DEXCOM INC | 47.51 | 31.67B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.51 | 26.70B |
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
LUCID DIAGNOSTICS INC
360 Madison Avenue, 25th Floor
New York City NEW YORK US
Employees: 70
Phone: 12129494319
The current stock price of LUCD is 1.38 USD. The price increased by 11.29% in the last trading session.
The exchange symbol of LUCID DIAGNOSTICS INC is LUCD and it is listed on the Nasdaq exchange.
LUCD stock is listed on the Nasdaq exchange.
12 analysts have analysed LUCD and the average price target is 3.7 USD. This implies a price increase of 167.93% is expected in the next year compared to the current price of 1.38. Check the LUCID DIAGNOSTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LUCID DIAGNOSTICS INC (LUCD) has a market capitalization of 149.70M USD. This makes LUCD a Micro Cap stock.
LUCID DIAGNOSTICS INC (LUCD) currently has 70 employees.
LUCID DIAGNOSTICS INC (LUCD) has a support level at 1.02. Check the full technical report for a detailed analysis of LUCD support and resistance levels.
The Revenue of LUCID DIAGNOSTICS INC (LUCD) is expected to grow by 14.65% in the next year. Check the estimates tab for more information on the LUCD EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LUCD does not pay a dividend.
LUCID DIAGNOSTICS INC (LUCD) will report earnings on 2025-11-11, before the market open.
LUCID DIAGNOSTICS INC (LUCD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.03).
The outstanding short interest for LUCID DIAGNOSTICS INC (LUCD) is 7.7% of its float. Check the ownership tab for more information on the LUCD short interest.
ChartMill assigns a technical rating of 8 / 10 to LUCD. When comparing the yearly performance of all stocks, LUCD is one of the better performing stocks in the market, outperforming 88.7% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to LUCD. Both the profitability and financial health of LUCD have multiple concerns.
Over the last trailing twelve months LUCD reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS increased by 15.57% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -175.38% | ||
ROE | -862.6% | ||
Debt/Equity | 3.22 |
12 analysts have analysed LUCD and the average price target is 3.7 USD. This implies a price increase of 167.93% is expected in the next year compared to the current price of 1.38.
For the next year, analysts expect an EPS growth of 29.66% and a revenue growth 14.65% for LUCD